Turkish Abstract Abstract Article PDF Similar Articles Mail to Author

¹M.D. Associate Professor, Necmettin Erbakan University Faculty of Medicine, Department of Ophthalmology, Konya/TURKEY
²M.D. Asistant Professor, Necmettin Erbakan University Faculty of Medicine, Department of Ophthalmology, Konya/TURKEY Choroidal neovascularization (CNV) is a common vision threatening complication of pathological myopia. Photodynamic therapy has been an established treatment for subfoveal myopic CNV for many years, but this treatment does not restore visual acuity and is associated with long-term chorioretinal atrophy. More recently, clinical trials investigating the efficacy and safety of anti-vascular endothelial growth factor (anti VEGF) agents in patients with myopic CNV have demonstrated substantial visual acuity gains and quality of life increases compared with photodynamic therapy. These enhanced outcomes provide updated evidence-based clinical management guidelines of myopic CNV. This review summarises the latest myopic CNV literature with anti VEGF agents in the context of clinical experience. Keywords : Choroidal neovascularization, anti VEGF theraphy